Artiva Biotherapeutics is an innovative, clinical-stage biopharmaceutical enterprise focused on advancing off-the-shelf, allogeneic natural killer (NK) cell therapies. Its proprietary platform is designed to treat severe B-cell-driven autoimmune conditions—such as systemic lupus and rheumatoid arthritis—and hematologic malignancies by leveraging innate immune mechanisms.